https://www.yiliao.com/index.php?action=history&feed=atom&title=E7090
E7090 - 版本历史
2026-04-19T00:04:23Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=E7090&diff=314524&oldid=prev
223.160.136.36：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-15T06:49:01Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[E7090]]</strong>（通用名：<strong>[[Taskirvatinib]]</strong>）是一种由[[卫材]]（[[Eisai]]）研发的强效、高选择性口服<strong>[[成纤维细胞生长因子受体]]</strong>（<strong>[[FGFR]]</strong>）[[酪氨酸激酶抑制剂]]（[[TKI]]）。它主要针对[[FGFR1]]、[[FGFR2]]及[[FGFR3]]亚型发挥[[竞争性抑制]]作用。[[E7090]]的设计旨在解决携带[[FGFR2基因融合]]或重排的<strong>[[胆管癌]]</strong>患者的临床需求，并曾获得日本厚生劳动省（[[MHLW]]）的[[SAKIGAKE]]（先驱药物）认定。截至2026年，[[E7090]]已在多项临床研究中证实其能显著抑制[[FGFR]]驱动的肿瘤[[增殖]]与[[血管生成]]，成为[[精准肿瘤学]]领域针对[[FGFR]]异常的新型重要治疗方案。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[E7090]]</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px;">[[Taskirvatinib]] · [[FGFR抑制剂]] · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 10px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[FGFR]]激酶域结合模型</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">主要靶点：[[FGFR1/2/3]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2263([[FGFR2]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">3689</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P21802</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[分子量]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">587.66Da</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[CAS]]登记号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">1414923-01-3</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">开发厂商</th><br />
<td style="padding: 12px; color: #0f172a;">[[卫材]]([[Eisai]])</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">作用机制：精准截断FGFR级联信号</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[E7090]]的作用机制主要聚焦于阻断由[[成纤维细胞生长因子]]（[[FGF]]）信号异常驱动的肿瘤演进：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[ATP]]竞争性结合：</strong>[[E7090]]能与[[FGFR]]激酶结构域的[[ATP]]结合位点高度结合，阻止受体自身的[[磷酸化]]，从而在源头上关闭下游通路。</li><br />
<li style="margin-bottom: 12px;"><strong>多通路阻断：</strong>通过抑制[[FGFR]]，[[E7090]]级联性下调了[[Ras/MAPK]]、[[PI3K/Akt]]以及[[JAK/STAT]]通路。这些通路是肿瘤细胞[[抗凋亡]]、[[细胞迁移]]和[[代谢重编]]的核心。</li><br />
<li style="margin-bottom: 12px;"><strong>优异的[[动力学]]特性：</strong>相比前代[[FGFR抑制剂]]，[[E7090]]展现了更慢的解离速率（[[Low Off-rate]]），这意味着更持久的靶点占用时间。</li><br />
<li style="margin-bottom: 12px;"><strong>针对[[融合基因]]：</strong>在[[胆管癌]]中，[[FGFR2]]发生[[染色体易位]]形成融合蛋白（如[[FGFR2-BICC1]]），[[E7090]]对此类变异具有极高的抑制灵敏度。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心临床研究矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">试验编号</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">研究人群/适应症</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">关键数据状态</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[NCT04245696]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[FGFR2]]融合阳性[[胆管癌]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[II期]]注册研究显示出卓越的[[客观缓解率]]([[ORR]])及[[DCR]]。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[肺癌探索队列]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[FGFR1]]扩增的[[鳞状肺癌]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">正在评估其在克服传统[[化疗]]耐药中的增效作用。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[实体瘤联合方案]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[FGFR]]变异患者 + [[PD-1抑制剂]]</td><br />
<td style="padding: 8px; border: 1px solid #3b82f6;">探索[[靶向]]与[[免疫]]联用对[[微环境]]的重塑效应。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：精准筛选与副反应管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[E7090]]的应用策略强调“[[标志物驱动]]”与“[[安全性]]预警”的双向结合：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[基因检测]]先行：</strong>给药前必须通过[[NGS]]检测[[FGFR2]]融合状态。在[[胆管癌]]中，约10-15%的患者存在此类突变，是该药的绝对[[获益人群]]。</li><br />
<li style="margin-bottom: 12px;"><strong>[[高磷血症]]管理：</strong>这是[[FGFR抑制剂]]常见的[[类效应]]。需定期监测[[血磷]]水平。若血磷水平超过临界值，需采取[[低磷饮食]]或联用[[磷酸盐结合剂]]。</li><br />
<li style="margin-bottom: 12px;"><strong>[[眼部副作用]]监控：</strong>临床中需警惕[[视网膜]]色素上皮脱离（[[RPED]]）。建议患者在治疗期间每3个月进行一次[[OCT]]检查。</li><br />
<li style="margin-bottom: 12px;"><strong>[[序贯治疗]]考量：</strong>主要针对[[吉西他滨]]联合[[顺铂]]一线治疗失败后的[[后线解救]]方案。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[FGFR2基因融合]]：</strong>胆管癌的核心致癌驱动力，也是[[E7090]]精准打击的“坐标”。</li><br />
<li style="margin-bottom: 8px;"><strong>[[SAKIGAKE认定]]：</strong>日本特有的绿色审评通道，旨在加速具有重大临床价值的创新药上市。</li><br />
<li style="margin-bottom: 8px;"><strong>[[高磷血症]]：</strong>由于抑制[[FGFR1]]干扰了[[肾脏]]对磷的排泄导致的代谢反应。</li><br />
<li style="margin-bottom: 8px;"><strong>[[佩米替尼]] (Pemigatinib)：</strong>全球首个上市的同类药物，常作为[[E7090]]的临床对标物。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Furuse J, et al. (2022).</strong> <em>Phase I/II study of E7090, a selective FGFR1–3 inhibitor, in patients with cholangiocarcinoma and other advanced solid tumors.</em> <strong>[[Cancer Medicine]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：该研究奠定了E7090在携带FGFR2融合的胆管癌患者中高客观缓解率的临床基础。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Eisai R&D Division. (2025).</strong> <em>Molecular selectivity and pharmacological advantages of Taskirvatinib (E7090) over broad-spectrum TKIs.</em> <strong>[[Science Direct Oncology]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：解析了该分子在维持靶点高占用率及减少脱靶毒性方面的结构优势。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[E7090]] ([[Taskirvatinib]]) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[FGFR1]]•[[FGFR2]]•[[FGFR3]]•[[MAPK]]•[[PI3K]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">适应症</td><br />
<td style="padding: 10px 15px; color: #334155;">[[肝内胆管癌]]•[[子宫内膜癌]]•[[尿路上皮癌]]•[[鳞状肺癌]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[卫材]]•[[FDA]]•[[PMDA]]•[[NMPA]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[针对FGFR激酶域突变的耐药研究]]•[[联合抗血管生成药物]]•[[早期新辅助治疗应用]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.136.36